Bristol Myers CEO Hedges On How Much Milvexian AFib Data Its First Press Release Will Show

Chris Boerner said detail in the release must be balanced against saving data for a medical meeting, and a $2 billion savings goal is on track.

Share
Bristol Myers CEO Hedges On How Much Milvexian AFib Data Its First Press Release Will Show

Bristol Myers Squibb, the drugmaker behind Opdivo and Eliquis, would not promise how much detail its first-quarter atrial fibrillation readout for milvexian will carry, CEO Chris Boerner told analysts on the third-quarter earnings call on Thursday. He said more specifics in the press release "will likely be important," but the company must weigh that against saving data for a conference.

Detail versus a medical conference

A Bernstein analyst asked whether the first-quarter press release would carry real details or simply a positive or negative verdict, and how long investors would wait for validation. The analyst noted the non-inferiority margin on the primary endpoint will be critical and a wide range can count as success.

Boerner, who is Board Chair and CEO, said the company will "work to give an accurate view of the outcome" and give a sense of the opportunity in atrial fibrillation. He added that the company needs to balance that against presenting the data "in a more fulsome way at a future medical conference," and will work with its partner on the program to strike that balance.

He also said he would be "remiss" not to remind everyone that the study sits within a much broader and richer pipeline. Milvexian atrial fibrillation results are expected in the first quarter of 2027; Phase three data in secondary stroke prevention are due before year-end.

Deal appetite and the $2 billion savings goal

A BMO Capital Markets analyst noted a disconnect between Bristol's business-development spending over the past 12 months and that of some peers, and asked whether it reflects valuation discipline. Boerner said deals remain a top capital-allocation priority and the company is "certainly not waiting for anything." If a deal makes financial sense, he said, Bristol has the capacity to be "in the mix."

Chief Financial Officer David Elkins said a strategic productivity initiative is on track to deliver $2 billion of efficiencies by the end of 2027. He also said the company expects Eliquis to step down by $1.5 billion to $2 billion in 2027, and that it ended the quarter with about $13 billion in cash.

A quarter of growth and a raised outlook

Total revenue rose 7% to about $13.1 billion in the third quarter, Elkins said, with growth-portfolio revenue up 12% to $7.7 billion. Diluted earnings per share were $1.35, including a 58-cent hit from acquired in-process research and development, net of licensing income.

The company raised its full-year revenue guidance, and its 2026 adjusted earnings-per-share range is now $6.35 to $6.55. Eliquis revenue rose 26% to about $4.7 billion, and the company still expects full-year Eliquis growth of 20% to 25%.

The next dated milestone is Phase three milvexian data in secondary stroke prevention before year-end, ahead of the atrial fibrillation readout in the first quarter of 2027.

Sources

More on Bristol-Myers Squibb

All Bristol-Myers Squibb (BMY) coverage →